skip to content
Primary navigation


DrugAplenzin (bupropion HBr)

October 2009

Therapeutic area - Antidepressant

Approved indication

Aplenzin (bupropion hydrobromide) is indicated for the once daily treatment of major depressive disorder.

Aplenzin is a hydrobromide salt formulation of bupropion. Bupropion is otherwise available as the hydrochloride salt as IR, ER and XR Wellbutrin brand and generic products.


Patients have been tried on bupropion at an equivalent dose and have shown a therapeutic response and have tolerated the dose AND the patient is going to be taking only ONE tablet of Aplenzin per day.

Switching from Wellbutrin (bupropion hydrochloride)

Total Bupropion HCl daily dose Equivalent bupropion hydrobromide (Aplenzin) dose
450 mg 522 mg
300 mg 348 mg
150 mg 174 mg


Aplenzin is a hydrobromide salt formulation of bupropion. It relies on its claim of bioequivalence to Wellbutrin XL for clinical and safety profiling. Wellbutrin XL is also a once daily formulation. Aplenzin does not offer either a cost or clinical benefit.

State Reimbursement to Pharmacies 10-2009

Aplenzin 522 mg $14.25
Aplenzin 348 mg $6.25
Aplenzin 174 mg $4.75


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top